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Abstract  
In South Africa, the high prevalence of familial hypercholesterolaemia (FH) among Afrikaners, Jews, 
and Indians as a result of founder genes is in striking contrast to its reported virtual absence in the 
black population in general. In this study, the molecular basis of primary hypercholesterolaemia was 
studied in 16 Africans diagnosed with FH. DNA analysis using three screening methods resulted in 
the identification of seven different mutations in the coding region of the low density lipoprotein 
(LDLR) gene in 10 of the patients analysed. These included a 6 bp deletion (GCGATG) accounting for 
28% of defective alleles, and six point mutations (D151H, R232W, R385Q, E387K, P678L, and R793Q) 
detected in single families. The Sotho patient with missense mutation R232W was also heterozygous 
for a de novo splicing defect 313+1G→A. Several silent mutations/polymorphisms were detected in 
the LDLR and apolipoprotein B genes, including a base change (g→t) at nucleotide position −175 in 
the FP2 LDLR regulatory element. This promoter variant was detected at a significantly higher 
(p<0.05) frequency in FH patients compared to controls and occurred in cis with mutation E387K in 
one family. Analysis of four intragenicLDLR gene polymorphisms showed that the same 
chromosomal background was identified at this locus in the four FH patients with the 6 bp deletion. 
Detection of the 6 bp deletion in Xhosa, Pedi, and Tswana FH patients suggests that it is an ancient 
mutation predating tribal separation approximately 3000 years ago.  
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Autosomal dominant hypercholesterolaemia (ADH) is most commonly caused by mutations in the 
low density lipoprotein receptor (LDLR) gene causing familial hypercholesterolaemia (FH), or in the 
apolipoprotein B (ApoB) gene causing familial defective apo B (FDB).1 2  These biochemical defects 
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result in the precipitation of excess cholesterol and clinical characteristics include tendon 
xanthomata and premature coronary heart disease (CHD). The estimated incidence of both FH and 
FDB is approximately 1 in 500 in most white populations.  
In the Afrikaner population of South Africa, the prevalence of FH has been increased to 
approximately 1 in 70, as a consequence of a founder effect following the introduction of at least 
three defectiveLDLR gene alleles by European settlers.3-5 This is in striking contrast to the 
apparently low prevalence of FH in the black population, reported to have migrated from central 
Africa to the south in three main groups, the Ngunis (Xhosa, Tembu, Swazi, and Zulu) along the east 
coast, the Sothos (South Sotho, North Sotho/Pedi, West Sotho/Tswana) who settled further west on 
the Transvaal highveld, and the Vendas living in the northern Transvaal area.6 7 We suspect that FH 
is not frequently recognised in Africans because of altered clinical expression and not because of a 
lower mutation prevalence compared to most other populations. Previous studies have indicated 
that the mutational mechanisms giving rise to germline mutations are largely a function of the local 
DNA sequence environment.8-10  
Since the situation in South Africa is ideal for studies of underlying lipid related genetic differences 
among population groups,11 we attempted to identify black hypercholesterolaemics to determine 
the spectrum of mutations in the promoter and coding region of the LDLR gene and in exon 26 of the 
ApoB gene. FDB has not previously been studied in the South African black population, but was 
found to be rare in other South African populations, most likely because of a “negative” founder 
effect that diluted the frequency of the common ApoB 3500 mutation in the immigrants relative to 
their parent populations.12  
Subjects and methods  
SUBJECTS 
Blood samples were collected from 56 black patients attending lipid clinics in South Africa, after 
obtaining informed consent and ethical approval from the regional Review Committees. Details on 
clinical features and ethnicity were provided by the referring clinicians. Sixteen patients with a 
diagnosis of “classical” or “probable” FH, including two FH homozygotes, were selected for extensive 
mutation analysis for the coding and promoter region of the LDLR gene and exon 26 of the ApoB 
gene. Blood samples were also obtained from 38 of their family members (table 1). Classical FH (12 
probands) was defined as the occurrence of pretreatment total cholesterol (TC) >7 mmol/l, with the 
presence of tendon xanthomata or premature CHD or both in the index case or a first degree 
relative. Probable FH (four probands) was defined by the same pretreatment cholesterol level and 
primary hypercholesterolaemia or premature CHD or both in the family (table 1). DNA samples of 
the 40 lipid clinic patients without the FH phenotype, but who had hyperlipidaemia or normal lipid 
profiles in the presence of vascular disease, were included for analysis of specific regions of theLDLR 
gene. Ninety six people drawn from the same population (19 Pedis, 21 Sothos, 27 Xhosas, and 29 
Zulus) were sampled as controls. TC, high density lipoprotein cholesterol (HDLC), and triglyceride 
(TG) determinations and extraction of genomic DNA were performed using standard methods.13 
Plasma LDL cholesterol (LDLC) concentrations were calculated with the Friedewald formula 
(LDLC=TC−(HDL+TG/2.18)).14 
MUTATION DETECTION  
Heteroduplex single strand conformation polymorphism (HEX-SSCP) analysis was performed in South 
Africa15 and denaturing gradient gel electrophoresis (DGGE) in Denmark16 and Scotland17 to 
screen polymerase chain reaction (PCR) amplified genomic DNA for mutations in theLDLR and 
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ApoBgenes. For HEX-SSCP analysis, the exon specific primers described by Jensen et al 18 were used, 
while the promoter region of the LDLR gene was amplified using primers 5′-
GAGGCAGAGAGGACAATGGC-3′ and 5′-CCACGTCATTTACAGCATTTCAATG-3′. Base changes in the 
promoter region were numbered according to Hobbs et al,19 after adding an additional A within the 
AAAA stretch preceding repeat 1, which is missing from the published sequence.20 PCR products 
showing aberrant electrophoresis patterns were sequenced on both strands with a PCR Product 
Sequencing kit (Amersham) or an automated sequencer ABI 373A or both.  
HAPLOTYPE ANALYSIS  
Haplotype analysis using four LDLR gene polymorphisms was performed according to Theart et al.21 
Microsatellite markers VWA31, F1A1, and TH01 (Profiler kit, Applied Biosystems) were used to test 
for biological consistency in two families.  
STATISTICAL ANALYSIS  
Allele frequencies were determined by allele counting. Testing for significance of heterogeneity in 
mutation frequencies among patient and control groups was based on the chi-square and Fisher's 
exact tests.  
Results 
Extensive DNA screening of the LDLRgene in 16 black FH patients, using both the DGGE and HEX-
SSCP screening methods, showed six missense mutations in individual families and a 6 bp deletion in 
four probands (table 1).22 The deletion (FH Cape Town-1), previously described in a Xhosa FH 
homozygote,23 and missense mutations D151H and R385Q have not (yet) been reported in other 
populations. HaplotypeSmaI+/StuI+/AvaII− was associated with the deletion in all three FH 
heterozygotes and a homoallelic FH homozygote. Screening of the coding region in DNA of the four 
FH patients heterozygous for a base change (g→t) at nucleotide position −175 of the LDLR gene 
promoter resulted in the detection of a recycling deficient mutation E387K19 in the DNA of subject 
EF. Interestingly, this Pedi proband was found to be extremely heterogeneous at the DNA level, since 
a silent C to T base change was furthermore detected at nucleotide position 1104 in exon 8, in 
addition to two silent mutations in theApoB gene. The G to C change in the third base of codon 3540 
(T3540T) and the T to C change in the third base of codon 3552 (T3552T) in the ApoB gene have 
previously been reported in Nigerian and African-American subjects, respectively.17 One of the 
daughters of proband EF (II.3 in fig 1) carried two copies of the silentApoB mutation at codon 3540. 
RFLP analysis indicated that haplotypeSmaI+/StuI+/AvaII−/NcoI+ cosegregated with the −175t allele 
in the family (fig 1). This chromosomal background was also identified in two of the other probands 
with the sequence substitution at −175 in theLDLR promoter region, while 
haplotypeSmaI−/StuI+/AvaII+/NcoI+ was associated with the t allele in the Tswana proband (LM), 
who also carried the T3552T variant in the ApoBgene.  
In order to determine whether the two mutations identified in each of probands EF and SH occur in 
cis or in trans on their respective chromosomes, blood samples were obtained from additional family 
members for segregation analysis. Pedigree analysis in the family of EF showed that mutation E387K 
and the −175g→t variant occur on the same chromosome (fig 1). All the family members who 
inherited the 387K/−175t haplotype (I.1, I.2, II.2, II.4, III.2, and III.5) had abnormally high TC and LDLC 
levels. II.2, with a clinical diagnosis of heterozygous FH, was homozygous for the t allele at 
nucleotide position −175. This implies that her deceased father (husband of the index case) also 
carried the −175g→t promoter variant, but in the absence of mutation E387K. Her 
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normocholesterolaemic son (III.1), as well as her brother, inherited this paternal chromosome, the 
latter presenting with a moderately raised TC value. The proband's son (II.1) and one of her 
daughters (II.3) (confirmed by marker studies using highly informative microsatellites) had 
moderately raised plasma cholesterol concentrations in the absence of either the promoter variant 
or the exonic mutation, indicating that another unknown factor contributes to the abnormal lipid 
profile observed in this family. TC concentrations were found to be very low in the general black 
population (approximately 3 mmol/l) compared with other South African groups.24 25  
DNA screening of the 53 year old father of proband CK, diagnosed with homozygous FH, showed 
homozygosity for the t allele at nucleotide position −175. His TC and LDLC levels were 6.11 mmol/l 
and 4.29 mmol/l, respectively, which is comparable to that of a FH heterozygote. Plasma TG and 
HDLC concentrations were 1.49 mmol/l and 1.14 mmol/l, respectively, and the only clinical feature 
indicative of hyperlipidaemia in this obligate FH heterozygote was corneal arcus.  
HEX-SSCP analysis indicated that the splicing defect identified in exon 3 represents a de novo event 
in the family of SH, since it was not present in any of his close relatives analysed. Familial 
relationship was illustrated by transmission of the exon 5 mutation (R232W) from the father (72 
years, TC 4.1 mmol/l), and was further substantiated by marker studies using three highly 
informative microsatellites (data not shown). Mutation R232W was absent in the 
normocholesterolaemic brother (30 years, TC 3.5 mmol/l) and sister (42 years, TC 3.3 mmol/l) of the 
proband. Their mother, aged 62 years, presented with a TC level of 2.9 mmol/l. It was therefore not 
possible to determine whether the splice mutation occurred in cis in the proband on the paternal 
chromosome bearing mutation R232W, or in trans on the normal maternal chromosome.  
Subsequent DNA screening of 96 controls from the general black population comprising 56 Ngunis 
(27 Xhosas, 29 Zulus) and 40 Sothos (19 Pedis, 21 Sothos) resulted in the identification of six subjects 
(four Ngunis (one Xhosa, three Zulus) and two Sothos (one Pedi, one Sotho)) heterozygous (6%) for 
the −175t allele. Although the number of patients analysed is small, the frequency of this allele 
appeared to be higher within each tribal group (2/6 Ngunis and 2/10 Sothos with FH) compared to 
the controls (4/56 Ngunis and 2/40 Sothos). An overall statistically significant difference (p<0.05) 
was observed between the presence of the rare t allele in the general black population (0.03) 
compared to its frequency of 0.13 in the patients diagnosed with classical or probable FH (χ2=5.916, 
1 df, p=0.0149). We furthermore detected five carriers of the −175g→t polymorphism among 40 
lipid clinic patients without the FH phenotype (13%), showing an intermediate allele frequency of 
0.06. This was not significantly different from the frequencies observed in the FH (χ2=1.326, 1 df, 
p=0.249) or control (χ2=1.474, 1 df, p=0.224) groups. Variant −175g→t was also detected in 1/47 
DNA samples of controls from the Venda tribe studied by Ehrenborg et al,25which was absent in 
more than 300 whites screened.26  
Discussion 
Numerous low density lipoprotein receptor (LDLR) gene mutations (>600) have been identified in FH 
patients, but genetic data on black African populations are rare.19 22 23 27 A striking finding is that 
a 6 bp deletion predominates in a small number (5/18) of FH patients (this study)19 23 28 identified 
in the South African black population, where this lipid disorder is thought to be rare. This deletion in 
exon 2 removes an aspartic acid and a glycine from the first cysteine rich ligand binding repeat 
ofLDLR, and impairs its transport but not lipoprotein binding in fibroblasts.23 Frequent detection of 
a deleterious mutation can be the result of consanguinity, recurrent mutational events, genetic drift, 
founder gene effect, multiple introduction of the mutation into a population, or heterozygote 
advantage.  
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The 6 bp deletion identified originally in a homoallelic Xhosa FH homozygote,23 and now also in a 
homozygous Pedi and three FH heterozygotes (Pedi and two Tswanas) on the same haplotype, have 
not (yet) been reported in other populations. These findings largely exclude the likelihood of a 
recurrent mutational event because of slipped mispairing or multiple entries of the deletion 
mutation into the black population. Detection of the deletion in different tribes suggests that it 
originated in Africa approximately 3000 years ago before tribal separation.29 Although FH patients 
with the deletion may therefore be distantly related, family ties cannot at present explain its 
relatively high prevalence among black FH patients. The apparently low prevalence of FH in South 
African blacks and the large population size furthermore argue against a founder effect. It is, 
however, possible that the deletion mutation was propagated and inherited within a small group of 
people who later evolved separately into different African tribes. Another plausible explanation is 
that this deleterious deletion mutation may be associated with a selective advantage in Africa. 
Already in 1990 Hobbs et al,30 noted that the presence of several founder mutations in different 
South African population groups4 31 may be indicative of a Darwinian selection that favours the 
heterozygous state in this region of the world. Since the most likely selective agent in Africa would 
be infectious diseases, the finding that LDLR deficient mice are protected against lethal 
endotoxaemia and severe gram negative infections32 supports the likelihood of such an 
evolutionary selection mechanism conferring a survival advantage. In addition to binding and 
inactivating endotoxin, lipoproteins also bind certain viruses and inhibit their infectivity.33  
Although the family data presented in this study show that the −175g→t polymorphism residing in a 
cis acting element in the LDLR promoter34 does not cause the FH phenotype in affected subjects, 
further studies are warranted to investigate the likelihood that this variant may influence disease 
expression. The possibility that the significantly higher frequency of the −175g→t promoter 
polymorphism in South African black FH patients compared to controls (p<0.05) is caused by linkage 
disequilibrium with another downstream mutation causing the FH phenotype was excluded by 
haplotype studies showing that the rare t allele was associated with differentLDLR haplotypes. This 
allele furthermore cosegregated with missense mutation E387K in one family. These different 
chromosomal backgrounds may be the result of recombination events, reflecting the age of the 
−175g→t variant. Compared to whites, blacks are considered older in evolutionary terms35 and can 
therefore be expected to have accumulated variation over longer times. It is possible that the 
−175g→t polymorphism did not spread to other parts of the world, thereby explaining its apparent 
absence in whites (this study).18 36 The African origin of the −175g→t variant was confirmed by 
detection of the rare t allele at a low frequency in control DNA samples obtained from Nigerians and 
African-Americans.26 African-Americans originated mostly from the western African coast and 
arrived in North America between the 16th and 19th centuries.  
One Sotho proband was heterozygous for a known splicing defect in intron 3 (313+1G→A) and for 
the R232W mutation in exon 5. In all the patients with mutation 313+1G→A studied to date, the 
splicing defect is associated with a clinical picture of severe hypercholesterolaemia and early CHD.37 
38 Patient SH had a TC concentration of 13 mmol/l, but it is uncertain whether this high level is 
solely because of the 313+1G→A mutation or whether there is an additional effect of the 
downstream R232W mutation. Family studies could not rule out the possibility of a double mutation, 
but showed that the splicing defect is the consequence of a de novo mutation. None of the family 
members of SH were hypercholesterolaemic, including his 72 year old father (LDLC 1.9 mmol/l), who 
was heterozygous for mutation R232W. This finding indicates that R232W does not affect LDLR 
function or, alternatively, that clinical expression of this missense mutation is altered by other 
genetic/environmental factors.  
Although the missense mutations identified have not been characterised further, they are likely 
contributors to the FH phenotype in our patient sample, since all the codon changes involve 
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conserved amino acids and were not detected in the normal population. Screening for mutations 
causing FDB16 17 39 resulted in the identification of two silent mutations, T3540T and T3552T (data 
not shown), previously described in a Nigerian and African-American subject, respectively.17 Failure 
to identify disease related mutations in all the patients studied may be because of limitations 
imposed by the screening techniques used, clinical misdiagnosis of FH, or mutations in other genes 
causing the ADH phenotype.40 41  
Both the Zulu and Pedi patients clinically diagnosed with homozygous FH presented with relatively 
low pretreatment TC levels (<15 mmol/l) for this severe condition1 and neither have yet suffered 
from CHD. The relatively mild expression of homozygous FH in these subjects largely precludes an 
estimation of the prevalence of heterozygous FH in the South African black population based on the 
prevalence of homozygous FH. Raised plasma cholesterol levels causing FH in a family frequently 
remain undetected until the occurrence of coronary events or clinical signs indicative of FH is 
observed in one or more family members. This may particularly be the case in the South African 
black population, as hypercholesterolaemics with lipid profiles compatible with the diagnosis of 
heterozygous FH frequently lack xanthomata characteristic of this condition (this study).42 None of 
the FH heterozygotes with the relatively severe 6 bp deletion in exon 223 presented with CHD. These 
findings provide evidence that FH is probably underdiagnosed in the South African black population, 
most likely as a consequence of altered expression of FH related mutations. This may be the result of 
interaction with other genetic and environmental factors, including a prudent diet.11 Data provided 
by us and others43-45therefore suggest that clinical/biochemical criteria for the diagnosis of FH 
need to be different by country/population and that DNA methods may assist in making a definitive 
disease diagnosis.  
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Table  
Table 1  
Characteristics of African probands analysed for LDLR and apo B gene mutations 
Index 
Ancest
ry 
Sex Age 
TC TG HDL 
LD
L 
Clinic
al 
LDLR 
gene 
sequen
ce 
change
s  
Apo B 
gene 
sequen
ce 
change
s  
Relativ
es 
tested  (mmol/l)1-152   
CM Xhosa F 52 8.5 
2.
7 
1.
5 
5.8 
CH
D 
R793Q  0         
MX Xhosa M 50 
10.
8 
2.
0 
0.
9 
9.0 
Arc, 
Xan 
−175g→t  0         
AN Swazi F 58 
10.
1 
0.
9 
1.
3 
8.4 
Arc, 
Xan
, 
CH
D 
D151H  0         
AS Swazi M 49 8.0 
1.
0 
2.
1 
5.4 
Arc, 
CH
D 
P678L  0         
AM
1-150  
Swazi/Zul
u 
F 56 8.3 
1.
5 
1.
9 
5.7 Arc   11         
CK1-
151  
Zulu M 26 
13.
8 
0.
8 
1.
3 
12.
1 
Arc, 
Xan 
−175g→t  1         
SH Sotho M 33 
12.
7 
2.
2 
1.
2 
10.
5 
Arc, 
Xan 
313+1G
→A; 
R232W 
 4         
RK Sotho M 58 
10.
7 
2.
3 
1.
0 
8.6 
CH
D 
R385Q  0         
KN1
-151  
Pedi F 32 
14.
9 
0.
8 
1.
4 
13.
1 
Arc, 
Xan 
6-bp del, 
6-bp del 
 0         
EF Pedi F 56 
13.
1 
1.
1 
1.
2 
11.
4 
Arc, 
PV
D, 
CH
D 
E387K; 
−175g→t
; C347C 
T3552
T; 
T3540
T 
10         
LP Pedi F 61 9.4 
0.
8 
0.
9 
8.1 
Arc, 
Xan 
6-bp del  3         
CN1
-150  
Pedi F 57 7.4 
2.
6 
0.
9 
5.3 
Arc, 
PV
D 
  6         
RM
1-150  
Pedi/Tswa
na 
F 54 
10.
8 
0.
4 
1.
3 
9.3 
Arc, 
?Xa
n 
  3         
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Index 
Ancest
ry 
Sex Age 
TC TG HDL 
LD
L 
Clinic
al 
LDLR 
gene 
sequen
ce 
change
s  
Apo B 
gene 
sequen
ce 
change
s  
Relativ
es 
tested  (mmol/l)1-152   
LM
1-150  
Tswana F 56 6.1 
1.
8 
1.
8 
3.5 
Arc, 
CH
D 
−175g→t 
T3552
T 
0         
RL Tswana F 30 9.3 
0.
8 
1.
7 
7.2 
Arc, 
Xan 
6-bp del  0         
CS Tswana F 47 7.9 
0.
7 
1.
7 
5.9 Arc 6-bp del  0         
 The majority of mutations summarised in this table were included in a recent mutation 
update.22  
 Reference plasma cholesterol concentrations in the general black population are given in ref 
24. 
 TC, total cholesterol; TG, triglycerides, HDL, high density lipoprotein cholesterol; LDL, low 
density lipoprotein cholesterol; CHD, coronary heart disease; PVD, peripheral vascular 
disease; Arc, arcus cornealis; Xan, xanthomata.  
 1-150 Probable FH.  
 1-151 Clinical FH homozygotes.  
 1-152 Pretreatment concentrations, except for proband LM for whom pretreatment levels 
were not available.  
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Figure 
Figure 1 
Pedigree of proband EF (arrow) clinically diagnosed with heterozygous FH. Clinical, biochemical, and 
genetic data are provided for people for whom DNA samples were available. Those with raised 
plasma cholesterol levels are indicated by dark (mutation positive for E387K) and shaded symbols. 
The presence (+) or absence (−) of LDLR gene mutations and recognition sites for SmaI, StuI, AvaII, 
and NcoI are indicated. 
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